Clock’s ticking. After an expected FDA nod for Descovy as the second HIV PrEP drug, Gilead Sciences now has one year to convince its current Truvada takers to switch over before generics hit. The FDA ...

As FDA panel experts gear up to debate the merits of Gilead’s Descovy for HIV prevention, the question doesn’t seem to be whether it’s worthy of an indication in men, the largest part of the market.

Add Yahoo as a preferred source to see more of our stories on Google. Today, the U.S. Food and Drug Administration approved Gilead’s drug Descovy to be used as PrEP, an HIV prevention strategy that ...

George Froehle, PA, a primary care clinician at CentraCare in rural St. Cloud, Minnesota, has been prescribing the HIV prevention pill tenofovir disoproxil fumarate plus emtracitabine (TDF/FTC) since ...

A major health insurer has notified policy holders that it will no longer cover Gilead Sciences’ drug Descovy for pre-exposure prophylaxis, or PrEP, and will instead require them to switch to Truvada, ...

Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points. In the phase 3, ...

The panel voted against recommending the prevention pill for use in cisgender women due to inadequate data on efficacy in this patient population. An FDA panel has backed Gilead’s HIV prevention drug ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 ...

This post is part of Outward, Slate’s home for coverage of LGBTQ life, thought, and culture. Read more here. In October, the U.S. Food and Drug Administration approved the drug Descovy to be used as a ...

Gilead Sciences, the drug giant behind the blockbuster HIV prevention pill Truvada, won FDA approval on Thursday to market Descovy — a medication already used by those who have HIV — as its ...